Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,043 | 3,404 | 1,124 | 1,464 | 3,830 |
| Receivables | 224 | 96 | 98 | 108 | 108 |
| Other current assets | 0 | 0 | 0 | 3 | 11 |
| TOTAL | $2,460 | $4,697 | $2,289 | $2,758 | $5,855 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 336 | 378 | 419 | 461 | 503 |
| TOTAL | $336 | $378 | $419 | $461 | $503 |
| Total Assets | $2,796 | $5,074 | $2,708 | $3,219 | $6,358 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 482 | 982 | 1,936 | 916 | 1,275 |
| Accrued Expenses | 370 | 408 | 542 | 761 | 786 |
| TOTAL | $1,307 | $1,636 | $3,333 | $2,031 | $2,517 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 10 | 18 | 27 | 32 | 55 |
| TOTAL | $10 | $17 | $26 | $31 | $48 |
| Total Liabilities | $1,316 | $1,654 | $3,359 | $2,061 | $2,565 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 565 | 506 | 489 | 210 | 191 |
| Common Shares | 1 | 1 | 0 | 0 | 0 |
| Retained earnings | -126,642 | -124,674 | -121,557 | -118,053 | -115,363 |
| Other shareholders' equity | -329 | -328 | -328 | -327 | -326 |
| TOTAL | $1,479 | $3,421 | $-651 | $1,158 | $3,793 |
| Total Liabilities And Equity | $2,796 | $5,074 | $2,708 | $3,219 | $6,358 |